SequelSEC

Harmony Biosciences Holdings, Inc. HRMY

Pharmaceutical Preparations · CIK 0001802665 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$959.90M
Fiscal year ended 2026-06-30
Operating income
$230.65M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $959.90M and net income of $181.27M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Harmony Biosciences Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Harmony Biosciences Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$959.90M
Cost of revenue$235.90M
Gross profit$723.99M
Operating income$230.65M
Net income$181.27M
Research & development$220.87M
Weighted-average diluted sharesUnavailable
Pretax income$241.20M
Income tax expense$59.93M
Diluted EPSUnavailable
Selling, general & administrative$272.47M
General & administrative$147.93M
Selling & marketing$124.54M

Balance

Harmony Biosciences Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$549.77M
Total assets$1.37B
Current assets$814.33M
Total liabilities$373.84M
Current liabilities$234.07M
Total equity incl. NCI$999.24M
Temporary (mezzanine) equityUnavailable
Inventory$6.36M
Accounts receivable$111.00M
GoodwillUnavailable
Long-term debt$133.96M
Accounts payable$21.68M

Cash flow

Harmony Biosciences Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$355.08M
Capital expendituresUnavailable
Investing cash flow-$337.57M
Financing cash flow-$13.79M
Net change in cash$3.72M
Stock-based compensation$40.90M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Harmony Biosciences Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin75.4%
Operating margin24.0%
FCF marginUnavailable
SBC / revenue4.3%
Current ratio3.48x
Revenue YoY growth24.3%
Net margin18.9%
R&D / revenue23.0%
CapEx / revenueUnavailable
Long-term debt / equity0.13x
Effective tax rate24.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HRMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.